Celgene

Novo Nordisk, Takeda, Servier, Celgene among top sponsors

Sunday, March 1, 2015

Relationships between drug sponsors and investigative sites have become more effective during the past two years, according to a new CenterWatch survey, as the initiatives top sponsors have implemented in recent years to address site burdens—such as increased protocol complexity and insufficient study support—are beginning to have a positive impact.

[Read More]

Adimab, Sanofi collaborate on bispecific antibodies

Monday, February 9, 2015

Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

[Read More]

Zymeworks, Celgene collaborate

Thursday, January 22, 2015

Zymeworks, a privately held biotherapeutics company based in Vancouver, has formed a collaboration and licensing agreement with Celgene for the research, development and commercialization of bi-specific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric platform.

[Read More]

Celgene collaborates with Sutro Biopharma, inks option to acquire

Friday, October 24, 2014

Sutro Biopharma, located in South San Francisco, has entered into a strategic collaboration and option agreement with Celgene to discover and develop multispecific antibodies and antibody drug conjugates (ADCs). This new agreement follows the December 2012 collaboration between the two companies and focuses on the field of immuno-oncology, while further broadening the Sutro platform for discovery, development and manufacture of best-in-class biotherapeutics.

[Read More]

Bristol-Myers Squibb, Celgene collaborate on combination regimen

Thursday, August 21, 2014

Bristol-Myers Squibb and Celgene have established a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of BMS’ investigational PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), and Celgene’s nab technology-based chemotherapy Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), in a phase I study.

[Read More]